本帖最后由 老马 于 2012-1-13 21:20 编辑
' E: j' x# u5 ~" s2 r8 X* j7 s0 o- Y7 m; O9 N1 r2 C5 ]6 O; v; o; g
爱必妥和阿瓦斯丁的比较' t! ~+ }5 Q4 w) n- Z
8 _" f6 M: | z3 g g3 l) b7 P* whttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/$ c3 i* s6 g) V+ n
6 ]3 e& Y% J2 z' n7 l& I* t
9 W5 x: v: B, {4 K0 Lhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/5 b# }+ O/ @6 q, u
==================================================
$ {9 v+ X0 D: x) J% HOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)+ \% @6 {" o7 h z3 @( M, F" r7 ~
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
+ ^; C/ f1 M5 z: @. w9 `Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; Q; T: |5 S7 l1 |4 y2 r' v
|